Enact Holdings, Inc. has confirmed that Thomas J. McInerney will resign from its Board of Directors, effective December 31, 2026. This announcement, made on October 30, 2026, marks a significant leadership change for the company. McInerney's decision to step down is not linked to any disputes or disagreements regarding the company's operations or policies.
Enact Holdings, Inc. operates under the SIC code 6411, which encompasses insurance agents, brokers, and services. The company is publicly traded on the Nasdaq under the ticker ACT and is classified as a large accelerated filer. Its headquarters is located in Raleigh, North Carolina.
According to the recent SEC filing, McInerney intends to remain on the Board and Compensation Committee until his resignation takes effect at the end of December. His departure is expected to influence the company's strategic direction as it continues to operate in a competitive insurance market.
This change may affect various stakeholders, including employees, investors, and clients, as the company adjusts to new leadership dynamics. The filing does not specify what the next steps will be following McInerney's resignation.
Enact Holdings, Inc. is incorporated in the state of Delaware and operates under the fiscal year ending on December 31. The company has a Central Index Key (CIK) number of 0001823529, which is used for SEC filings.
The filing also confirms that Thomas J. McInerney's resignation is not connected to any disputes or disagreements regarding the company's operations, policies, or practices, emphasizing a smooth transition in leadership. McInerney's tenure has been significant, and his decision to resign may lead to a reevaluation of the company's strategic initiatives.
As of the date of the filing, Enact Holdings, Inc. continues to be classified as a large accelerated filer, which indicates a certain level of compliance and reporting obligations under SEC regulations. The company maintains a business address at 8325 Six Forks Road, Raleigh, North Carolina, and can be contacted via phone at (919) 846-4100.
The filing does not provide information regarding potential successors for McInerney or any upcoming board meetings to discuss the transition. Additionally, there are no details on how the company plans to address McInerney's departure in terms of leadership structure or strategic direction.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






